Will taking CN-105 reduce serious adverse events during my upcoming noncardiac operation?
Research indicates that taking CN-105 can lower the risk of serious side effects during noncardiac operations for older adults. A specific clinical trial showed that patients receiving this drug experienced fewer grade 2 or higher adverse events than those given a placebo 1.
What the research says
In a phase 2 randomized clinical trial, older adults scheduled for noncardiac surgery received intravenous CN-105 or a placebo 1. The study found that the CN-105 group had fewer grade 2+ adverse events compared to the placebo group 1. This trial specifically looked at reducing postoperative neuroinflammation and delirium in patients 60 years or older 1.
Other research explains how neuroinflammation works in the brain. For example, lactate production and transport in the central nervous system create environments that determine the level of neuroinflammation 3. Additionally, molecules like ISG15 regulate inflammatory responses, and targeting these pathways is a strategy for treating inflammatory diseases 2. While the TWEAK-Fn14 axis is also involved in neuroinflammation and brain injury, CN-105 targets a different mechanism related to apoE protein signaling 14.
What to ask your doctor
- Does my upcoming noncardiac surgery qualify for the CN-105 trial protocol regarding patient age and surgery type?
- What are the specific exclusion criteria for taking CN-105 before my operation?
- How might CN-105 affect my specific risk of postoperative delirium or neuroinflammation?
- Are there any interactions between CN-105 and other medications I am currently taking?
This question is drawn from common patient questions about Emergency Medicine and answered using cited medical research. We do not provide individualized advice.